This study provides critical data for managing vaccine shortages during yellow fever outbreaks, suggesting that optimizing immunization strategies for young children requires balancing dose reduction with long-term antibody persistence.
Literature Overview
This article, titled 'Immunogenicity of fractional one-fifth and one-half doses of 17DD yellow fever vaccine compared with full dose in children aged 9–23 months in Uganda: a phase 4, single-blind, randomised clinical trial,' published in the journal 'Lancet (London, England),' systematically explores the immunogenicity differences and safety profiles of 1/5 and 1/2 doses of the 17DD yellow fever vaccine compared to the full dose in children aged 9–23 months in Uganda. Through a randomized controlled trial design, the study rigorously evaluates seroconversion rates and neutralizing antibody titer changes for different fractional doses over the short term (4 weeks) and long term (1 year and 13–48 months).Background Knowledge
Yellow fever is a mosquito-borne viral disease endemic to tropical regions of Africa and South America, with mortality rates reaching 30%–60% in severe cases. Vaccination remains the most effective control measure; however, during outbreak response scenarios characterized by vaccine shortages, full-dose vaccination often fails to cover all high-risk populations. Currently, fractional dosing strategies (e.g., 1/5 dose) of the yellow fever virus vaccine (17D strain) are recommended by the World Health Organization for adults, but data regarding safety and efficacy in children under 2 years of age have long been scarce. A key challenge in disease prevention and control is that the infant immune system is not yet mature and may be interfered with by maternal antibodies, leading to a less robust response to live attenuated vaccines compared to adults. Furthermore, existing research has largely focused on the 17D-213 strain or adult populations, creating a significant bottleneck in studies targeting the 17DD strain's ability to induce neutralizing antibodies in young children. This study addresses this gap by comparing 1/5, 1/2, and full doses to explore optimal immunization strategies for the most vulnerable infant population during vaccine shortages, balancing short-term protection with long-term immune memory.
Research Methods and Experiments
The authors conducted a Phase 4, single-blind, randomized, non-inferiority clinical trial. The study was carried out across three public health facilities in Uganda, enrolling 1,784 healthy children aged 9–23 months, who were randomly assigned in a 1:1:1 ratio to receive either a 1/5 dose (0.1 mL), a 1/2 dose (0.25 mL), or a full dose (0.5 mL) of the 17DD yellow fever vaccine. Follow-up assessments were conducted at 4 weeks (V1), 1 year (V2), and 13–48 months (V3) post-vaccination. Key evidence was derived from the detection of yellow fever virus-specific neutralizing antibodies using the 50% plaque reduction neutralization test (PRNT50) as the gold standard. The study evaluated not only seroconversion rates but also analyzed the dynamic trajectory of antibody titers using geometric mean titers (GMT) and longitudinal mixed-effects models, while monitoring adverse events to assess safety.Key Conclusions and Perspectives
Research Significance and Prospects
These findings have profound implications for drug development (vaccine strategy formulation) and clinical monitoring during yellow fever outbreaks. The study confirms that the 1/2 dose may provide more durable protection than the 1/5 dose in young children, offering empirical evidence for developing age-stratified fractional dosing guidelines. Future research should focus on the immune response mechanisms to live attenuated vaccines across different age groups in disease modeling, particularly the interaction between maternal antibody interference and immune maturity, to further optimize global vaccine reserve strategies.
Conclusion
Through a rigorous randomized clinical trial, this study systematically evaluated for the first time the immunogenicity of 1/5 and 1/2 fractional doses of the 17DD yellow fever vaccine in children aged 9–23 months. The results indicate that while fractional doses can induce high levels of seroconversion in the short term, meeting the urgent needs of outbreak response, the full dose or 1/2 dose may offer superior advantages in long-term immune persistence, particularly for infants aged 9–12 months. This finding provides critical scientific evidence for yellow fever prevention and control strategies, suggesting that when vaccine supply is limited, a careful balance between dose and age factors must be struck to avoid excessive dilution leading to insufficient long-term protection. In the translation of laboratory data to clinical decision-making, this study emphasizes the importance of optimizing immunization strategies for specific age groups, laying the foundation for global public health authorities to formulate precise vaccination plans in resource-constrained environments, ensuring the maximum protection for the most vulnerable children.
